Malignant Pleural Mesothelioma Market Drug Class (Premetrexed and Combination, Cisplatin and Combination, Carboplatin and Combination, Gemcitabine and Combination, Vinorelbine and Combination and Other Combination), By Route of Administration (Oral and Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Oncology Centers), By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa); Trend Analysis, Competitive Market Share & Forecast, 2016-26
Published:
March 2020
Report Code:
BWC19437
Available Format:
PDF PDF Icon
Pages:
180

malignant pleural mesothelioma market bwc19437

COVID-19

We've been tracking the direct impact of COVID-19 on this market, and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Contact our sales team for more details at

Contact Now

Global Malignant Pleural Mesothelioma Market Forecast and Trends

The global Malignant Pleural Mesothelioma market has reached USD Billion in 2019 and estimated to reach USD Billion in 2026 and anticipated to grow by CAGR of 7.6% during the forecast period 2020-2026. The global market for malignant pleural mesothelioma will likely incur a favorable boost from increased healthcare spending seen in multiple parts of the world, coupled with the availability of better treatment prognosis for malignant pleural mesothelioma. Overall, the global malignant mesothelioma market is also seeing increased adoption of combination therapies. In the treatment of malignant pleural mesothelioma, many companies promote the increasing use of chemotherapy and immune-oncology procedures.

Global Malignant Pleural Mesothelioma Market: Overview

Malignant pleural mesothelioma is a rare and aggressive cancer that develops around the lungs in a thin layer of tissue called pleura. The microscopic inhalation of asbestos fibers causes malignant pleural mesothelioma. Once the person is inhaling asbestos particles, the human body fails to remove asbestos needle-like fibers from the lungs.  The incidence of malignant pleural mesothelioma in Europe is around 20 per million inhabitants, according to the NIH, and it is increasing globally. This will then require the need to develop innovative treatments for malignant pleural mesothelioma, which will drive market growth. Malignant pleural mesothelioma signs include dyspnea, recurrent dry or raspy cough, chest pain, difficulty swallowing, also known as dysphagia, and also known as hemoptysis, coughing up the blood. Since the mid 20th century, the occurrence of Malignant pleural mesothelioma has increased. The appearance of malignant pleural mesothelioma within and between nations is markedly variable.

Growth Drivers

Rising exposure to asbestos (industrial pollutant)

People exposed to asbestos are at a higher risk of developing malignant pleural mesothelioma. Within contaminated areas, the chance of malignant pleural mesothelioma is increased by 2 to 10 fold as compared with non-polluted areas. Besides, people exposed to a high dose of radiation, zeolites (minerals chemically associated with asbestos), and suffering from simian virus 40 are at risk of developing malignant pleural mesothelioma and indirectly contribute to the global market for malignant pleural mesothelioma with the significant growth rate.

Increasing expenditure on R&D coupled with increasing pipeline molecule

The therapeutic pipeline is expected to see significant growth in the forthcoming years on the market for malignant pleural mesothelioma due to higher incidence rates, increased air pollution, increased geriatric population, and increased healthcare expenditure. In addition, the advancement of innovative therapy and the launch of advanced treatment options are likely to provide the malignant pleural mesothelioma market with lucrative growth opportunities over the 2020-2026 forecast period.

Restraint

Delay in Diagnosis

The key factor expected to hamper the growth of the global market for malignant pleural mesothelioma is a long latent period between onset and symptom, lack of effective treatment, and low surveillance rates over the 202-2026 forecast period.

Global Malignant Pleural Mesothelioma Market: Drug Class

Based on drug class, the global malignant pleural mesothelioma market segmented into Premetrexed and Combination, Cisplatin and Combination, Carboplatin and Combination, Gemcitabine, and Combination, Vinorelbine and Combination and Other Combination. Among the group is considered a combination of pemetrexed and cisplatin as the normal first-line treatment of malignant pleural mesothelioma. It is the most effective treatment for Chemotherapy. In a recent study to test cisplatin and pemetrexed called Mesothelioma Avastin Cisplatin Pemetrexed Trial (MAPS), the addition of bevacizumab showed significantly improved survival rates for patients with minimal side effects of malignant pleural mesothelioma.


Global Malignant Pleural Mesothelioma Market: Distribution Channel

Based on Distribution Channel, the market is diversified as hospital pharmacies, retail pharmacies, and oncology centers. Amidst the category oncology centers expected to cater global malignant pleural mesothelioma market with a high growth rate. Followed by oncology centers, hospital pharmacies, and retail pharmacies anticipated to witness significant growth rate during the forecast period of 2020-2026.

Global Malignant Pleural Mesothelioma Market: Regional Insights

Global Malignant Pleural Mesothelioma market segmented into five regions, including North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America is leading the market for malignant pleural mesothelioma, followed by Europe due to higher incidence and prevalence rates, an increase in the geriatric population, and increased demand advance therapy. The Asia Pacific is an emerging market for malignant pleural mesothelioma due to the development of healthcare infrastructure, patient awareness, and increased government spending in the healthcare sector. Low recognition of patients, lack of proper care, and high therapy costs are factors that narrow the Middle East & Africa market for malignant pleural mesotheliomas.


Malignant Pleural Mesothelioma: Competitive Landscape

Malignant Pleural Mesothelioma market is fragmented owing to the presence of number of large-sized companies that hold the majority share of AstraZeneca Plc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, Eli Lilly and Company, Teva Pharmaceuticals, Boehringer Ingelheim GmbH, Mylan N.V., Fresenius Kabi AG, Sun Pharmaceuticals Industries Ltd, Corden Pharma International GmbH, Concordia International Corp and Other Prominent Players.

The objective of the Study:

To analyze and forecast the global market size of the Malignant Pleural Mesothelioma.

Analyzing careful market segmentation and estimating value-based market size through region-based segmentation.

The global Malignant Pleural Mesothelioma is divided into five regions: North America, Europe, Asia-Pacific, Middle East & Africa, Latin America.

To outline, categorize, and forecast the global AI in the agricultural market based on drug class, route of administration, and distribution channel with the region.

To examine competitive developments in the global Malignant Pleural Mesothelioma market, such as technological advancement, services, and regulatory framework.

To emphasize the impact study of market dynamics variables such as users, constraints, opportunities, and challenges.

Profiling key players strategically and analyzing their market shares comprehensively, together with detailing the competitive environment for market leaders.

Scope of the Report:

Attribute

Details

Years Considered

Historical data – 2016-2019

Base Year – 2019

Forecast – 2020 – 2026

Facts Covered

Revenue in USD Million/Billion

Market Coverage

U.S, Canada, Germany, UK, France, Italy, Spain, Brazil, Mexico, Argentina, Japan, South Korea, China, India, UAE, South Africa, Saudi Arabia

Product/Service Segmentation

By Drug Class, Route of Administration, and Distribution Channel

Key Players

AstraZeneca Plc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, Eli Lilly and Company, Teva Pharmaceuticals, Boehringer Ingelheim GmbH, Mylan NV, Fresenius Kabi AG, Sun Pharmaceuticals Industries Ltd, Corden Pharma International GmbH, Concordia International Corp, Other Prominent Players.

By Drug Class

·         Pemetrexed and Combination

·         Cisplatin and Combination

·         Carboplatin and Combination

·         Gemcitabine and Combination

·         Vinorelbine and Combination

·         Other Combination

By Route of Administration

·         Oral

·         Parenteral

By Distribution Channel

·         Hospital Pharmacies

·         Retail Pharmacies

·         Oncology Centers

By Region: 

·         North America

·         Europe

·         Asia Pacific

·         Latin America

·         Middle East & Africa

Business Questions Answer by the Report

How will the market drivers, restraints, and opportunities affect the market dynamics?

What will be the market size in terms of value and volume and market statistics with a detailed classification?

Which segment dominates the market or region, and one will be the fastest-growing, and why?

A comprehensive survey of the competitive landscape and the market participant players

Analysis of strategy adopted by the key player and their impact on other players.

Customization Scope for the Client

Client satisfaction is our first and last priority, and that’s why BlueWeave Consulting offers customization according to Company’s specific needs. The following customization options are available for the report:

Additional Company Information

With five additional company detail analysis

Additional country analysis

Detailed segment analysis

Why Choose us

  • 24/5 Research support

    Get your queries resolved from an industry expert. Request for a free product review before report purchase.

  • Coustom Research Service

    Ask the Analyst to customize an exclusive study to serve your research needs.

  • Quality & Accuracy

    offers best quality reports based on various authentic and accurate data findings.

  • Data Visualization

    As the business world is changing dynamically every day. We need to stay pin point in relation to data management and optimum data utilization

  • Information security

    We never share your personal and confidential information. Your personal information is safe and secure with us.